Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

Lahuerta, Juan José; Mateos, María Victoria; Martínez‐López, Joaquín; Rosiñol, Laura; Sureda, Anna; Rubia, Javier de la; García-Laraña, José; Martínez-Martínez, Rafael; Hernández-García, M; Carrera, Dolores; Besalduch, Joan; Arriba, Felipe de; Ribera, Josep‐Marǐa; Escoda, Lourdes; Hernandez-Ruiz, B.; García-Frade, Javier; Rivas-González, Concepción; Alegre, Adrián; Bladé, Joan; Miguel, Jesús F. San

doi:10.1200/jco.2008.17.9721

Cited by 264 publications

(199 citation statements)

References 38 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…5,6,27,28 We have confirmed the prognostic effect of attaining XVGPR in both the transplant and non-transplant settings. We also show that the superior PFS accorded by achieving XVGPR was able to translate to a longer OS.…”

Section: Discussionsupporting

confidence: 60%

Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma

Tan

Lao

Loh

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 60%

Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma

Tan

Lao

Loh

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Achievement of CR after autologous SCT has become an important surrogate marker for prolonged survival. 35 Achievement of a better response before autologous SCT by the use of novel agents may also improve the post-transplant outcome. 1 As also seen in the current study, allogeneic SCT is associated with a high CR rate.…”

Section: Discussionmentioning

confidence: 99%

Allogenic hematopoietic stem‐cell transplantation with reduced‐intensity conditioning in patients with refractory and recurrent multiple myeloma

Shimoni

Hardan

Ayuk

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Allogeneic stem cell transplantation (SCT) with myeloablative conditioning is potentially curative therapy for myeloma, but is reportedly associated with a high risk of nonrecurrence mortality (NRM). Reduced-intensity conditioning (RIC) allows for the reduction of NRM, but the recurrence rate is increased. The role and timing of allogeneic SCT in the disease course remains controversial. To the authors' knowledge, there are limited data regarding the long-term outcome of RIC in the recurrent/refractory setting. METHODS: A retrospective analysis was conducted of SCT outcomes in 50 patients who received RIC for recurrent/refractory myeloma between the years 2001 and 2004. All patients were given fludarabine-melphalan based conditioning and stem cell grafts from a related (n ¼ 27) or unrelated donor (n ¼ 23). RESULTS: The median age was 53 years. Forty-seven patients failed a prior autologous SCT. Thirty patients were in disease remission at the time of SCT and 20 had stable or progressive disease. With a median follow-up of 6.4 years (range, 5-7.9 years), the overall and progression-free survival (PFS) rates were 34% and 26%, respectively. The NRM rate was 26%. Adverse prognostic factors for survival included SCT not in remission, long duration of disease (>5 years from diagnosis), and transplantation from a female donor to a male recipient. The 7-year PFS in 19 patients with none of these adverse prognostic factors was 47%. Chronic graft versus host disease and the achievement of complete remission after SCT were associated with improved outcome. CONCLUSIONS: Allogeneic SCT can result in long-term PFS in a subset of myeloma patients who fail prior therapy and should be considered early after failure and after achieving remission. Cancer 2010;116;3621-30.

show abstract

“…The overall goal is to increase CR rates post HDM that is also associated with long-term OS in patients with MM. 36 Disadvantages of this approach are possible side effects, risk of worsening of organ functions and consecutively delay of HDM.…”

Section: Should Induction Chemotherapy Be Used Before Hdm?mentioning

confidence: 99%

Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis

Schönland

Dreger

Witte

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

Abstract: Quality of response post-transplantation, notably CR, is significantly associated with EFS and OS prolongation in newly diagnosed patients with MM. There were trends toward similar associations with pretransplantation response status.

Cited by 264 publications

References 38 publications

Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma

Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma

Allogenic hematopoietic stem‐cell transplantation with reduced‐intensity conditioning in patients with refractory and recurrent multiple myeloma

Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis

Contact Info

Product

Resources

About